What does COLE PHARMACEUTICALS do?

COLE PHARMACEUTICALS is a wholesaler in Mont-Saint-Guibert. Private Limited, started on 28 February 2017, 1 establishment.

What is the address of COLE PHARMACEUTICALS?

The registered office of COLE PHARMACEUTICALS is located at Rue André Dumont 7, 1435 Mont-Saint-Guibert.

Is COLE PHARMACEUTICALS still active?

Yes. According to the CBE (29 October 2026) COLE PHARMACEUTICALS is active, legal situation “Normale toestand”, started on 28 February 2017.

Is COLE PHARMACEUTICALS registered on Peppol?

Yes, COLE PHARMACEUTICALS is registered on the Peppol network with ID 0208:0671904152.

What is the enterprise number of COLE PHARMACEUTICALS?

The enterprise number of COLE PHARMACEUTICALS is BE0671904152.

When was COLE PHARMACEUTICALS founded?

COLE PHARMACEUTICALS was founded on 28 February 2017.

Who are the directors of COLE PHARMACEUTICALS?

According to the 2025 annual accounts, the directors of COLE PHARMACEUTICALS are: JEAN-MARIE VANDEPLAS , CLAUDE LUBICKI, GUILLAUME DE VIRON .

Is COLE PHARMACEUTICALS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 February 2017; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did COLE PHARMACEUTICALS make in 2025?

COLE PHARMACEUTICALS recorded a loss after taxes of € 390,094 in financial year 2025.

What is the revenue of COLE PHARMACEUTICALS?

As a small company, COLE PHARMACEUTICALS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -168,161.

COLE PHARMACEUTICALS (Private Limited)

Dossier COLE PHARMACEUTICALS, printed on 29 October 2026 from databakkes.be/en/0671904152/cole-pharmaceuticals. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 56 % of short-term debt in 2025; threshold 65 %.
Figures corrected NBB

Corrected annual account filed for 2022.

Financials

Financial year 2025

COLE PHARMACEUTICALS from Mont-Saint-Guibert, company number BE0671904152, closed financial year 2025 with a result of € -390,094 after tax. For that financial year COLE PHARMACEUTICALS recorded a gross margin of € -168,161 and equity of € 468,254. Compared with financial year 2024, the result moved from € -592,788 to € -390,094. The company made a loss. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.

What it is worth Growing

€ 468,254

▲ € 1.2 million vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -390,094

▲ 34 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 668

▲ € 554 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -285,163.

People and assets in 2025

Vehicles and equipment

€ 1,406

▼ 19% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 14 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 844,300

▼ 11% vs 2024

€ 62,500 is repaid this year. At this pace the long-term loan is gone in ≈ 14 years.

Owed to suppliers

€ 160,639

▼ 79% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -313,660 Gross margin 2022: € -313,660 First fiscal year in the series	€ -491,082 Gross margin 2023: € -491,082 ▼ € 177,422 vs 2022 (€ -313,660) Unfavourable step	€ -423,335 Gross margin 2024: € -423,335 ▲ € 67,746 vs 2023 (€ -491,082) Favourable step	€ -168,161 Gross margin 2025: € -168,161 ▲ € 255,174 vs 2024 (€ -423,335) Favourable step	▲ € 255,174
Profit after taxes	€ -408,859 Profit after taxes 2022: € -408,859 First fiscal year in the series	€ -602,280 Profit after taxes 2023: € -602,280 ▼ € 193,422 vs 2022 (€ -408,859) Unfavourable step	€ -592,788 Profit after taxes 2024: € -592,788 ▲ € 9,492 vs 2023 (€ -602,280) Favourable step	€ -390,094 Profit after taxes 2025: € -390,094 ▲ € 202,694 vs 2024 (€ -592,788) Favourable step	▲ € 202,694
Equity	€ -116,993 Equity 2022: € -116,993 First fiscal year in the series	€ -137,864 Equity 2023: € -137,864 ▼ € 20,870 vs 2022 (€ -116,993) Unfavourable step	€ -730,652 Equity 2024: € -730,652 ▼ € 592,788 vs 2023 (€ -137,864) Unfavourable step	€ 468,254 Equity 2025: € 468,254 ▲ € 1.2 million vs 2024 (€ -730,652) Favourable step	▲ € 1.2 million
Total debts	€ 717,294 Total debts 2022: € 717,294 First fiscal year in the series	€ 892,990 Total debts 2023: € 892,990 ▲ 24% vs 2022 (€ 717,294) Unfavourable step	€ 1,724,108 Total debts 2024: € 1,724,108 ▲ 93% vs 2023 (€ 892,990) Unfavourable step	€ 1,044,415 Total debts 2025: € 1,044,415 ▼ 39% vs 2024 (€ 1,724,108) Favourable step	▼ 39%
Cash	€ 454 Cash 2022: € 454 First fiscal year in the series	€ 135,627 Cash 2023: € 135,627 ▲ € 135,173 vs 2022 (€ 454) Favourable step	€ 114 Cash 2024: € 114 ▼ € 135,513 vs 2023 (€ 135,627) Unfavourable step	€ 668 Cash 2025: € 668 ▲ € 554 vs 2024 (€ 114) Favourable step	▲ € 554
Retained profit	€ -1,674,963 Retained profit 2022: € -1,674,963 First fiscal year in the series	€ -602,280 Retained profit 2023: € -602,280 ▲ € 1.1 million vs 2022 (€ -1,674,963) Favourable step	€ -1,195,068 Retained profit 2024: € -1,195,068 ▼ € 592,788 vs 2023 (€ -602,280) Unfavourable step	€ -285,163 Retained profit 2025: € -285,163 ▲ € 909,906 vs 2024 (€ -1,195,068) Favourable step	▲ € 909,906
Bank debt	€ 313,883 Bank debt 2022: € 313,883 First fiscal year in the series	€ 481,241 Bank debt 2023: € 481,241 ▲ 53% vs 2022 (€ 313,883) Unfavourable step	€ 952,010 Bank debt 2024: € 952,010 ▲ 98% vs 2023 (€ 481,241) Unfavourable step	€ 844,300 Bank debt 2025: € 844,300 ▼ 11% vs 2024 (€ 952,010) Favourable step	▼ 11%
Balance sheet total	€ 600,301 Balance sheet total 2022: € 600,301 First fiscal year in the series	€ 755,127 Balance sheet total 2023: € 755,127 ▲ 26% vs 2022 (€ 600,301) Unchanged	€ 993,456 Balance sheet total 2024: € 993,456 ▲ 32% vs 2023 (€ 755,127) Unchanged	€ 1,512,669 Balance sheet total 2025: € 1,512,669 ▲ 52% vs 2024 (€ 993,456) Unchanged	▲ 52%

Key figures of COLE PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to COLE PHARMACEUTICALS?

What happened at COLE PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 26, 2026 New annual accounts for financial year 2025: loss of € 390,094. filed late Source: NBB ↗
2023 GUILLAUME DE VIRON stepped down as director. NBB
2020 GUILLAUME DE VIRON became a director. NBB
2019 JEAN-MARIE VANDEPLAS became a director. NBB
2019 CLAUDE LUBICKI became a director. NBB
Mar 1, 2017 New establishment in Mont-Saint-Guibert. KBO
Feb 28, 2017 Start of the company according to the CBE. KBO

In short

From € 408,859 loss in 2022 to € 390,094 loss in 2025.

Original PDFs at the National Bank ↗

Management

SODINTEC FINANCES 11.3%

C&N HOLDING 10.5%

The stake of SODINTEC FINANCES, C&N HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

COLE PHARMACEUTICALS

Behind COLE PHARMACEUTICALS are JEAN-MARIE VANDEPLAS and CLAUDE LUBICKI. The shares are held by SODINTEC FINANCES (11.3%) and C&N HOLDING (10.5%).

Directors

According to the 2025 annual accounts

JEAN-MARIE VANDEPLAS

Director

Also active at: MEDICAL MARKETING CONCEPT

since 2019

CLAUDE LUBICKI

Director

Also active at: BIOEXPAND

since 2019

GUILLAUME DE VIRON

Director

Also active at: Inteliphage, AYCA Investment

since 2020 · until 2023

Shareholders

SODINTEC FINANCES

11.3%

C&N HOLDING

10.5%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue André Dumont 7

1435 Mont-Saint-Guibert

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

OPAL SOLUTIONS

€ 1 million gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0671.904.152

VAT number

BE 0671.904.152

Registered office

Rue André Dumont 7, 1435 Mont-Saint-Guibert

Names & denominations

COLE PHARMACEUTICALS · Cole Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

28 February 2017

Peppol

Active · Active since 2 Dec 2025

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Handelsbemiddeling in meubelen, huishoudelijke artikelen en ijzerwaren

View on CBE Public ↗ Annual accounts (NBB) ↗

COLE PHARMACEUTICALS

Warning lights

Financials

What happened to COLE PHARMACEUTICALS?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions